Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting

by Asymmetrex
May 12, 2020

 

In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed by Asymmetrex.

In particular, Sherley stressed that certification of the stability of the therapeutic doses of natural and gene-engineered tissue stem cells is essential for elevating the supply of stem-gene clinical trials to greater quality and reliability.

Related Posts

Take a look at these posts